Journal of Immunology Research; Ma Y, Shi L et. al.
Jun 28th, 2022 - To identify the effect of long noncoding RNA (lncRNA) FR215775 in regulating CD4+ T cells on murine models of allergic rhinitis (AR), the expression of lncRNA FR215775 in primary Th2 cells was detected through qRT-PCR. After knocking down the expression of lncRNA FR215775 via Sh-FR215775-Ads, Cell Counting Kit-8, cytometric bead array, and fluorescence-activated cell sorting were performed to d...
Disease Markers; Liu B, Chen L et. al.
Jun 28th, 2022 - Gastric cancer (GC) represents a universal malignant tumor of the digestive system. Stromal and immune cells belong to two main nontumor components exerting a vital function in the tumor microenvironment. Based on TCGA database, this study downloaded clinical information and gene profiles of GC. The ESTIMATE algorithm was adopted for evaluating the score of immune-infiltrating cells. This work ...
Disease Markers; Zheng Z, Yang Y et. al.
Jun 28th, 2022 - Dendritic cells (DC) initiate the immune response in the body. They can stimulate T cell activation, proliferation, and differentiation and ultimately participate in the immune response and the immune tolerance response. The purpose of this study was to coculture DCs and T cells and subcutaneously inject DCs transfected with miR-let-7i into rhesus monkey transplantations to verify the role of m...
https://doi.org/10.1186/s12985-022-01840-z 10.1186/s12885-019-5916-6 10.1093/carcin/bgs365 10.1093/jnci/djp180 10.1053/j.gastro.2007.09.002 10.1016/j.jhep.2014.04.041 10.1136/gut.2008.174029 10.1093/ndt/gfp737 10.1002/j.1460-2075.1992.tb05369.x 10.3892/ol.2014.2190 10.1056/NEJMra2022774 10.1016/j.jhep.2019.08.026 10.1038/nrc3262 10.1002/hep.31209 10.2217/hep-2019-0007 10.1038/s41590-020-0622-8 10.1016/j.jhep.2011.06.028 10.1038/s41586-020-03056-z 10.1016/j.molcel.2010.09.023 10.1083/jcb.201002021 10.1016/j.tig.2017.08.004 10.1158/1541-7786.MCR-07-0098 10.1093/carcin/bgr296 10.3390/md14090166 10.1002/hep.20615 10.1101/gr.978703 10.1101/cshperspect.a012872 10.1080/10409230591008161 10.1016/j.semcancer.2019.11.007 10.3390/cells8010016 10.3390/cancers12030562 10.21037/tgh.2018.06.09 10.1002/hep.25592 10.1038/s41416-019-0441-6 10.1038/s41575-019-0145-7 10.1016/j.cellimm.2017.12.007 10.1038/nature07205 10.4161/onci.20304 10.1038/nature09782 10.1038/cmi.2018.2 10.1126/science.1136880 10.1073/pnas.0807694106 10.1073/pnas.0911267106 10.1016/j.ccell.2016.09.004 10.1172/JCI120888 10.1080/15548627.2018.1427398
Virology Journal; Cheng B, Wang Q et. al.
Jun 28th, 2022 - Hepatitis B virus can induce hepatocellular carcinoma (HCC) by inducing a host immune response against infected hepatocytes. C-terminally truncated middle surface protein (MHBSt) has been reported to contribute to HCC through transcriptional activation in epidemiology studies, while the underlying mechanism of MHBSt-induced HCC is unknown. In this study, a premature stop at codon 167 in MHBS (M...
Microbiome Liu Y, Yang M et. al.
Jun 28th, 2022 - Well-balanced interactions between gut microbiota and the immune system are essential to prevent chronic intestinal inflammation, as observed in inflammatory bowel diseases (IBD). Toll-like receptor 4 (TLR4) functions as a sensor mediating the crosstalk between the intestinal commensal microbiome and host immunity, but the influence of TLR4 on the shaping of intestinal microbiota and immune res...
https://doi.org/10.1038/s41467-022-31379-0 10.1002/advs.202270066 10.1038/s41577-021-00662-4 10.1126/science.abl8487 10.1038/s41421-022-00383-5 10.1016/j.cell.2013.09.061 10.1126/science.abf6840 10.1038/s41590-018-0305-x 10.1016/j.cell.2020.06.008 10.1001/jama.2021.8565 10.1038/s41467-022-29477-0 10.1016/j.molimm.2022.01.009 10.1080/22221751.2021.2022440 10.1080/22221751.2022.2088406 10.1038/s41586-021-04388-0 10.1038/s41586-021-04387-1 10.1016/S1473-3099(20)30831-8 10.1038/s41591-021-01377-8 10.1016/j.vaccine.2021.05.063 10.1016/S2666-5247(21)00267-6 10.1056/NEJMc2119426 10.1038/s41541-022-00432-w
Nature Communications; Kaabi NA, Yang YK et. al.
Jun 28th, 2022 - NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluate the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in BBIBP-CorV recipients in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129). Three groups...
https://doi.org/10.1186/s12985-022-01842-x 10.1016/j.jviromet.2014.05.013 10.1016/j.cimid.2007.01.002 10.1111/cas.14069 10.1016/j.coviro.2011.08.003 10.7774/cevr.2015.4.1.1 10.2144/Oct0204 10.1016/j.ymthe.2004.09.019 10.1186/1756-9966-31-1 10.1016/bs.acr.2018.02.005 10.1016/j.cyto.2020.155082 10.1517/1472822.214.171.1249 10.18632/oncotarget.15098 10.2147/OTT.S249816 10.1016/S0140-6736(15)00239-1 10.1080/21645515.2020.1823778 10.1089/hum.2012.037 10.1586/erv.11.188 10.1128/mBio.03224-20 10.1146/annurev.immunol.25.022106.141609 10.1186/s13046-019-1084-4 10.1186/s12929-016-0238-3 10.3390/cancers12102831 10.1016/j.virusres.2018.12.014 10.15448/1980-6108.2018.3.30555 10.1002/jbm.a.31919 10.1016/j.imlet.2007.09.008 10.1038/mt.2008.196 10.1159/000477245 10.1089/hum.2013.102 10.1158/1535-7163.MCT-15-0742 10.1016/j.micpath.2019.04.028 10.1016/j.micpath.2020.104207 10.1158/0008-5472.CAN-05-3127 10.1038/sj.onc.1208911 10.1016/j.intimp.2015.07.014 10.3892/ol.2016.5114 10.1002/ijc.27534 10.1111/1348-0421.12569 10.3390/v7031429 10.1038/sj.gt.3301696 10.1002/jgm.529 10.3390/ijms19020594 10.1038/s41419-020-03221-2 10.1021/acs.nanolett.9b04094 10.3892/br.2021.1462 10.1016/j.jconrel.2020.03.029 10.4161/21624011.2014.955691 10.1038/sj.cgt.7700954 10.1016/j.bbrc.2016.05.088 10.1111/j.1365-2567.2007.02780.x 10.3389/fonc.2019.01401 10.1080/07357900802112693 10.1159/000334089
Virology Journal; Miri SM, Pourhossein B et. al.
Jun 26th, 2022 - MDA-7/IL-24 cytokine has shown potent antitumor properties in various types of cancer without exerting any significant toxicity on healthy cells. It has also been proved to encompass pro-immune Th1 cytokine-like behavior. Several E7 DNA vaccines have developed against human papillomavirus (HPV)-related cervical cancer. However, the restricted immunogenicity has limited their clinical applicatio...
Proceedings of the National Academy of Sciences of the Un... Çuburu N, Bialkowski L et. al.
Jun 25th, 2022 - Tumor infiltration by T cells profoundly affects cancer progression and responses to immunotherapy. However, the tumor immunosuppressive microenvironment can impair the induction, trafficking, and local activity of antitumor T cells. Here, we investigated whether intratumoral injection of virus-derived peptide epitopes could activate preexisting antiviral T cell responses locally and promote an...
Proceedings of the National Academy of Sciences of the Un... Beucher G, Blondot ML et. al.
Jun 25th, 2022 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections initiate in the bronchi of the upper respiratory tract and are able to disseminate to the lower respiratory tract, where infections can cause an acute respiratory distress syndrome with a high degree of mortality in elderly patients. We used reconstituted primary bronchial epithelia from adult and child donors to follow the...
Journal for Immunotherapy of Cancer; Renken S, Nakajima T et. al.
Jun 24th, 2022 - Adoptive cell therapy using cytotoxic lymphocytes is an efficient immunotherapy against solid and hematological cancers. However, elevated levels of reactive oxygen species (ROS) in the hostile tumor microenvironment can impair NK cell and T cell function. Auranofin, a gold (I)-containing phosphine compound, is a strong activator of the transcription factor Nrf2. Nrf2 controls a wide range of d...
https://doi.org/10.1038/s41467-022-31259-7 10.1056/NEJMoa2034577 10.1056/NEJMoa2035389 10.1016/S0140-6736(20)32661-1 10.1016/S0140-6736(21)01429-X 10.1016/S1473-3099(20)30831-8 10.15585/mmwr.mm7021e3 10.1093/cid/ciaa1275 10.1016/j.tmaid.2021.102246 10.1038/s41576-021-00408-x 10.1016/j.eclinm.2021.101129 10.1038/s41467-021-24514-w 10.1016/j.ebiom.2022.103904 10.1038/s41586-021-03777-9 10.1038/s41586-021-04385-3 10.1056/NEJMc2103022 10.1038/s41467-022-28089-y 10.1016/j.cell.2020.12.015 10.1016/j.immuni.2021.08.013 10.1038/s41467-021-24123-7 10.1126/science.abe3354 10.1038/s41586-020-2852-1 10.1038/s41564-021-00972-2 10.1016/j.chom.2021.02.019 10.1038/s41586-022-04441-6 10.1016/j.antiviral.2022.105253 10.1038/s41392-021-00552-0 10.1038/s41594-021-00652-z 10.1016/j.cell.2021.03.055 10.1016/j.cell.2021.03.036 10.1016/j.chom.2021.04.007 10.1038/s41392-021-00767-1 10.1016/j.cell.2021.06.020 10.1038/s41586-021-03944-y 10.1016/S0140-6736(21)02758-6 10.1038/s41586-021-03720-y 10.1126/science.abh1139 10.1038/s41467-020-20789-7 10.1093/cid/ciaa644 10.1172/jci.insight.123158 10.1016/j.immuni.2016.03.006 10.1038/nprot.2009.3 10.1016/S2666-5247(20)30004-5 10.1038/nmeth.4193 10.1038/nmeth.4169 10.1093/nar/gku340 10.1107/S0907444910007493 10.1107/S0907444909052925 10.1016/j.jsb.2006.06.010 10.1002/pro.3235 10.1128/JCM.00310-20
Nature Communications; Zhou B, Zhou R et. al.
Jun 24th, 2022 - The strikingly high transmissibility and antibody evasion of SARS-CoV-2 Omicron variants have posed great challenges to the efficacy of current vaccines and antibody immunotherapy. Here, we screen 34 BNT162b2-vaccinees and isolate a public broadly neutralizing antibody ZCB11 derived from the IGHV1-58 family. ZCB11 targets viral receptor-binding domain specifically and neutralizes all SARS-CoV-2...
Proceedings of the National Academy of Sciences of the Un... Castillo PE
Jun 24th, 2022 - Unique transsynaptic complexes enable long-term synaptic plasticity in a synapse-specific manner.|2022|Castillo PE,|immunology,immunology,
Journal for Immunotherapy of Cancer; Yamaguchi Y, Gibson J et. al.
Jun 24th, 2022 - The immune suppressive tumor microenvironment (TME) that inhibits T cell infiltration, survival, and antitumor activity has posed a major challenge for developing effective immunotherapies for solid tumors. Chimeric antigen receptor (CAR)-engineered T cell therapy has shown unprecedented clinical response in treating patients with hematological malignancies, and intense investigation is underwa...
Proceedings of the National Academy of Sciences of the Un... Xu YR, Shi ML et. al.
Jun 24th, 2022 - During viral infection, sensing of viral RNA by retinoic acid-inducible gene-I-like receptors (RLRs) initiates an antiviral innate immune response, which is mediated by the mitochondrial adaptor protein VISA (virus-induced signal adaptor; also known as mitochondrial antiviral signaling protein [MAVS]). VISA is regulated by various posttranslational modifications (PTMs), such as polyubiquitinati...
Journal for Immunotherapy of Cancer; Rouhani SJ, Yu J et. al.
Jun 23rd, 2022 - Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side effect profiles of these vaccines in this population is not well understood. Patients with cancer can be immunocompromised from chemotherapy, corticosteroids, or the cancer itself, which may affect cellular and/or humoral responses to vaccination. PD-1 is expressed on T effector cells, T fol...
JAMA Rubin R
Jun 22nd, 2022 - Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.|2022|Rubin R,|therapeutic use,drug therapy,immunology,therapeutic use,therapeutic use,therapeutic use,therapeutic use,therapeutic use,
Proceedings of the National Academy of Sciences of the Un... Zheng W, Wang X et. al.
Jun 22nd, 2022 - Behçet's disease (BD) is a chronic vasculitis characterized by systemic immune aberrations. However, a comprehensive understanding of immune disturbances in BD and how they contribute to BD pathogenesis is lacking. Here, we performed single-cell and bulk RNA sequencing to profile peripheral blood mononuclear cells (PBMCs) and isolated monocytes from BD patients and healthy donors. We observed p...
https://doi.org/10.1186/s12957-022-02667-2 10.3322/caac.21412 10.3322/caac.21492 10.1007/s12282-016-0680-9 10.1016/bs.pmbts.2019.01.005 10.3390/cells8070680 10.3389/fonc.2017.00060 10.3390/biom10111485 10.3389/fonc.2017.00154 10.1016/j.bbabio.2016.02.020 10.3389/fchem.2018.00108 10.1158/0008-5472.CAN-17-0307 10.1007/s13402-011-0023-y 10.3892/ijo.2012.1464 10.1007/s12672-013-0136-z 10.1186/1741-7015-4-16 10.1093/nar/gkx1090 10.1038/s41467-019-09234-6 10.1093/nar/gky1131 10.1186/1471-2105-14-7 10.1186/s13059-016-1070-5 10.1038/ncomms3612 10.1007/s10147-017-1122-1 10.1038/s41591-018-0136-1 10.1186/s12957-021-02214-5 10.1186/s12957-021-02301-7 10.1186/s12957-021-02377-1 10.1186/s12957-021-02347-7 10.1186/s12957-020-02026-z 10.1186/s12957-021-02124-6 10.1186/s12957-021-02387-z 10.1186/s12957-020-01974-w 10.1186/s12957-021-02441-w 10.1186/s12957-020-02019-y 10.1186/s12957-022-02492-7 10.1155/2021/7647139 10.1016/j.neo.2018.02.012 10.18632/oncotarget.9943 10.1159/000438588 10.1038/srep33648 10.18632/oncotarget.6704 10.1007/s13277-016-4836-1 10.3389/fcell.2015.00043 10.3892/ol.2019.10534 10.1158/0008-5472.CAN-19-1982 10.1038/s41429-021-00451-0 10.3389/fimmu.2018.03059 10.3389/fimmu.2018.00563 10.1038/s41571-020-0426-7 10.1016/j.ejphar.2021.173867
World Journal of Surgical Oncology; Fang Y, Liu J et. al.
Jun 22nd, 2022 - More and more evidence suggests that cancer is a mitochondrial metabolic disease recently and mitochondria dysfunction is critical to tumorigenesis. As a gatekeeper of mitochondria, the voltage-dependent anion channel 1 (VDAC1) is associated with the development of breast cancer (BC). However, its potential mechanism and clinical significance remain unclear; thus, in this research, we aimed to ...
Proceedings of the National Academy of Sciences of the Un... Hu ZI, Link VM et. al.
Jun 22nd, 2022 - Immune checkpoint inhibitors (ICIs) are essential components of the cancer therapeutic armamentarium. While ICIs have demonstrated remarkable clinical responses, they can be accompanied by immune-related adverse events (irAEs). These inflammatory side effects are of unclear etiology and impact virtually all organ systems, with the most common being sites colonized by the microbiota such as the ...
Journal for Immunotherapy of Cancer; Dettling DE, Kwok E et. al.
Jun 22nd, 2022 - Despite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of target antigen expression on normal tissues may not be tolerated. To overcome this, we engineered a novel conditionally active TCE design called COBRA (Conditional Bispecific Redirected A...